ArticleFrontiers in immunology2025
Glymphatic dysfunction in neuromyelitis optica spectrum disorder.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuromyelitis optica spectrum disorder (NMOSD) involves aquaporin-4-mediated astrocyte injury, potentially impairing the glymphatic system. We assessed glymphatic function using the diffusion tensor image analysis along the perivascular space (DTI-ALPS) index, choroid plexus (CP) volume, and perivascular space (PVS) metrics, and explored associations with disability and brain structure. Methods: Thirty-nine aquaporin-4 immunoglobulin G (AQP4-IgG)-positive NMOSD patients without overt intracranial lesions and twenty-one age- and sex-matched healthy controls underwent 3T MRI using three-dimensional fast spoiled gradient-echo (3D-FSPGR) and diffusion tensor imaging (DTI). Manual segmentation of CP was performed in ITK-SNAP, and an automated pipeline derived DTI-ALPS and normalized PVS. Clinical assessments included the Expanded Disability Status Scale (EDSS), Hamilton Anxiety Rating Scale (HAMA) and Hamilton Depression Rating Scale (HAMD), Fatigue Impact Scale (FIS), and Pittsburgh Sleep Quality Index (PSQI). Statistical analyses comprised group comparisons, partial correlations (age/sex-adjusted), Firth penalized logistic regression and multivariable linear regression model, with false discovery rate (FDR) correction. Results: Among 39 NMOSD patients and 21 matched healthy controls, NMOSD patients showed trends toward higher DTI-ALPS (1.47 ± 0.10 vs. 1.45 ± 0.17, p = 0.20), larger CP volume (1,616 ± 408 mm Conclusions: In NMOSD, subtle CP volume enlargement is associated with disability status and ventricular enlargement, suggesting the presence of glymphatic dysfunction. CP alterations may represent a potential imaging biomarker of disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.